Sven Stegemann, Graz University of Technology - Qepler Summits And Conferences

Sven Stegemann

Professor for Patient Centric Drug Development and Manufacturing
Graz University of Technology
Graz, Austria
Your global solution provider in the design, development and manufacturing of proven drug delivery devices for biotech, healthcare and pharma partners.Think in new dimensions. Study for the future. Together we will achieve more - through knowledge and technology at the Technical University in Graz

Sven Stegemann is professor of patient centric drug design and manufacturing at the Graz University of Technology, Austria.

Over the course of his 21-year career at Capsugel, he has worked as an advisor to major pharmaceutical companies on ways to improve the design, development and manufacture of pharmaceutical products so they better address the individual needs of patients. In his academic role, he focuses his research on the rational development of patient centric drug products and their associated manufacturing technologies, as well as education and training of students and young scientists.

He is the founder and chair of the AAPS Focus Group on Patient-Centric Drug Development, Product Design, and Manufacturing as well as the founder and President of the Geriatric Medicine Society e.V..

He recently started the industrial-academic collaboration partnership Patient Centric Medicine (PaCeMe) to suitable and meaningful guidance for patient centric drug product design.

He is the editor of the book “Developing Drug Products in an Aging Society - From Concept to Prescribing”, a multidisciplinary approach towards patient centric drug development for the older and multimorbid patient populations.

Related Sessions:

Inhaled Drug Delivery
Summit 2019

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 23 May 2019
  • Berlin, DE
  • Pharma
Day 2: Friday, 24 May 2019
BLOCK: FORMULATION, DEVELOPMENT & DESIGN.
CASE STUDY: Engineering particles to deliver high dosed and sensitive drugs to the lung using standard inhaler systems.
  • The changing portfolio of development compounds and challenges for pulmonary delivery
  • Formulation technologies for DPI to address these emerging challenges
  • Considerations for technology selection
  • Application of spray drying in DPI formulation
  • Case study
View Details

2nd Annual Inhaled
Drug Delivery Summit 2021

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 05 Aug 2021
  • Virtual,
  • Pharma
Day 2: Friday, 06 August 2021
CASE STUDY: From perception to use - the patient DPI product interface.
  • Patient characteristics and therapeutic complexity
  • DPI product administration from a patient perspective
  • The role of learning, intuition and standardization
  • TDPI product design to improve therapeutic outcomes
View Details